# Trial on Safety & Performance of TAXUS Element vs. XIENCE Prime Stent in Treatment of Coronary Lesion in Diabetics

Study · id `cardio:ct-nct03125772` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03125772](<https://clinicaltrials.gov/study/NCT03125772>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03125772

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1830 participants.

## Technical summary

Registry record NCT03125772. Randomized; single masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2015-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1830 participants (enrolled count; ClinicalTrials.gov record NCT03125772, source copy `cardio:ctgov-nct03125772-2017-04-24`, retrieved 2026-10-26)
- Start date: 2011-06 (registry gives no type) (ClinicalTrials.gov record NCT03125772, source copy `cardio:ctgov-nct03125772-2017-04-24`, retrieved 2026-10-26)
- Primary completion: 2015-05 (actual) (ClinicalTrials.gov record NCT03125772, source copy `cardio:ctgov-nct03125772-2017-04-24`, retrieved 2026-10-26)
- Completion: 2016-05 (actual) (ClinicalTrials.gov record NCT03125772, source copy `cardio:ctgov-nct03125772-2017-04-24`, retrieved 2026-10-26)
- Countries: India (ClinicalTrials.gov record NCT03125772, source copy `cardio:ctgov-nct03125772-2017-04-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03125772-2017-04-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Trial on Safety & Performance of TAXUS Element vs. XIENCE Prime Stent in Treatment of Coronary Lesion in Diabetics
- Acronym: Tuxedo
- Condition: Type 2 Diabetes
- Condition: Coronary Heart Disease
- Intervention (Device): TAXUS Element™ Paclitaxel-Eluting Stent System
- Intervention (Device): Xience PRIME Everolimus-Eluting Stent System
- Lead sponsor: Fortis Escorts Heart Institute
- Lead sponsor class: OTHER
- Collaborator: Boston Scientific Corporation
- Collaborator class: INDUSTRY
- Collaborator: Max Neeman Medical International Ltd.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as a collaborator: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: 1d3b9f2867be773715b69fef38c0ffd22c14de02c7fdf78cc645b7421442c0b2
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
